Omasa Mitsugu, Date Hiroshi, Sozu Takashi, Sato Tosiya, Nagai Kanji, Yokoi Kohei, Okamoto Tatsuro, Ikeda Norihiko, Tanaka Fumihiro, Maniwa Yoshimasa
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Cancer. 2015 Apr 1;121(7):1008-16. doi: 10.1002/cncr.29166. Epub 2015 Jan 6.
The efficacy of postoperative radiotherapy (PORT) for thymic epithelial tumors is still controversial. Using the Japanese Association for Research on the Thymus (JART) database, this study was aimed at clarifying the efficacy of PORT for Masaoka stage II and III thymic carcinoma and thymoma.
The JART database registered the records of 2835 patients collected from 32 Japanese institutions from 1991 to 2010. Thymic carcinoma and thymoma at stage II or III were extracted. The efficacy of PORT with respect to relapse-free survival (RFS) and overall survival (OS) was evaluated with the Kaplan-Meier method and Cox regression analysis.
There were 1265 patients in all: 155 thymic carcinoma cases (12.3%) and 1110 thymoma cases (87.7%). Eight hundred ninety-five (70.8%) were at stage II, and 370 (29.2%) were at stage III. Four hundred three cases (31.9%) underwent PORT. PORT for stage II and III thymic carcinoma was associated with increasing RFS (hazard ratio, 0.48; 95% confidence interval, 0.30-0.78; P = .003) but was not associated with OS (hazard ratio, 0.94; 95% confidence interval, 0.51-1.75; P = .536). PORT for stage II and III thymoma was not associated with RFS or OS (P = .350). A subgroup analysis of stage III thymoma showed no factor associated with the efficacy of PORT.
In this study, PORT did not increase RFS or OS for stage II or III thymoma but increased RFS for stage II and III thymic carcinoma.
术后放疗(PORT)对胸腺上皮肿瘤的疗效仍存在争议。本研究利用日本胸腺研究协会(JART)数据库,旨在阐明PORT对Masaoka II期和III期胸腺癌及胸腺瘤的疗效。
JART数据库记录了1991年至2010年从日本32家机构收集的2835例患者的资料。提取II期或III期胸腺癌和胸腺瘤患者。采用Kaplan-Meier法和Cox回归分析评估PORT对无复发生存期(RFS)和总生存期(OS)的疗效。
共有1265例患者:155例胸腺癌(12.3%)和1110例胸腺瘤(87.7%)。895例(70.8%)为II期,370例(29.2%)为III期。403例(31.9%)接受了PORT。II期和III期胸腺癌的PORT与RFS增加相关(风险比,0.48;95%置信区间,0.30-0.78;P = 0.003),但与OS无关(风险比,0.94;95%置信区间,0.51-1.75;P = 0.536)。II期和III期胸腺瘤的PORT与RFS或OS无关(P = 0.350)。III期胸腺瘤的亚组分析显示,没有因素与PORT的疗效相关。
在本研究中,PORT未增加II期或III期胸腺瘤的RFS或OS,但增加了II期和III期胸腺癌的RFS。